Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to compare oral anti-diabetic drug (OAD) combined with insulin vs. insulin alone in subjects with type 2 diabetes not adequately controlled on the current OAD therapy.
- Trial name
- NCT01720303
- Testing
- repaglinide, isophane human insulin, insulin
- Where
- 3 sites in China
- Volunteers
- 159 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus
Ligand Pharmaceuticals Incorporated is developing LGD-6972, a novel, orally-bioavailable addition to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Trial name
- L6972-02 (NCT02250222)
- Testing
- LGD-6972
- Where
- 3 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Ligand Pharmaceuticals
Type II Diabetes, Dyslipidemia
Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)
A Multi-center, Randomized, double-blind, active-controlled, phase 3 trial to evaluate the safety and efficacy of Metformin/Atorvastatin in subjects with Type II Diabetes and dyslipidemia.
- Trial name
- NCT02947620
- Testing
- Metformin/Atorvastatin 1500mg/40mg, QD, Metformin 1500mg, QD, Atorvastatin 40mg, QD
- Where
- South Korea
- Volunteers
- 185 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Improved Glycemic Control in Patients With Type 2 Diabetes
A Trial of HR17031 Injection With Hepatic Insufficiency
This study used a single-dose, open design to compare the pharmacokinetics of subjects with mild and moderate liver impairment and subjects with normal liver function.
- Trial name
- NCT05151705
- Testing
- HR17031 injection
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus, Type 2
A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus
Primary objective: To determine the optimal treatment algorithm for the clinical use of insulin glargine based on the incidence of severe hypoglycaemia.
- Trial name
- AT-LANTUS (NCT00399724)
- Testing
- Insulin glargine
- Volunteers
- 7,376 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Free Fatty Acids and Vascular Function in Subjects With Diabetes
This study will test the hypothesis that reduction in release of free fatty acids from adipocytes will restore insulin-mediated endothelium-dependent vasodilation and skeletal muscle glucose metabolism in subject with type 2…
- Trial name
- NCT00153179
- Testing
- acipimox
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 2
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea…
- Trial name
- NCT01106625
- Testing
- Canagliflozin, Metformin, Sulphonylruea
- Where
- 76 sites in United States, Australia and 10 more
- Volunteers
- 469 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Non-Insulin-Dependent
NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes
The purpose of this research study is to investigate the mechanism of action of a new investigational medication (drug), NNC 90-1170, which is being developed for the treatment of type 2 diabetes (adult onset type of diabetes.
- Trial name
- NCT00013910
- Testing
- NNC 90-1170
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Diabetes Mellitus, Type 2
The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)
The purpose of the study is to determine the contribution of endogenous Glucagon-like peptide 1 (GLP-1) to the postprandial secretion of insulin and glucagon and the incretin effect in healthy subjects and patients with type 2…
- Trial name
- DFG_5 (NCT01449019)
- Testing
- exendin(9-39)amide, saline, duodenal meal
- Where
- 2 sites in Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Chronic Kidney Disease, Diabetic Nephropathy
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
The study objective is to investigate the effects of three low doses of atrasentan on urinary albumin/creatinine ratio (UACR) levels in subjects with Type 2 diabetic nephropathy.
- Trial name
- NCT00920764
- Testing
- 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 92 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetes, Diabetes Mellitus, Type 2
Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes
This this trial is conducted in Europe. The aim of this trial is to compare glycaemic control of biphasic insulin aspart 30 (BIAsp 30) alone or combined with insulin aspart(IAsp) in patients previously treated with conventional…
- Trial name
- NCT01697631
- Testing
- biphasic insulin aspart 30, insulin aspart
- Where
- 12 sites in Poland
- Volunteers
- 131 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Effect of a High-fat Meal on the Pharmacokinetics of SHR3824 and Mass Balance Study in Healthy Subjects
This open-label, randomized, two-period, two-treatment (single doses of 10 mg SHR3824 fasted or fed), crossover study was conducted to evaluate the effect of a high-fat meal on the pharmacokinetics of SHR3824 and mass balance…
- Trial name
- NCT02353975
- Testing
- SHR3824
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type II Diabetes
Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity
The purpose of this study is to evaluate the safety and efficacy of a second generation EndoBarrier Liner compared to a study diet to treat Subjects with Type 2 Diabetes.
- Trial name
- NCT00985114
- Testing
- EndoBarrier, Diet + Lifestyle Counseling
- Where
- 3 sites in Netherlands
- Volunteers
- 77 people
- Sponsor
- Morphic Medical Inc.
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of flexible versus fixed dosing and simple versus stepwise titration with OD insulin degludec in inadequately treated subjects with…
- Trial name
- NCT01880736
- Testing
- insulin degludec
- Where
- 40 sites in Japan
- Volunteers
- 458 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to compare efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in combination with metformin in subjects with type 2 diabetes…
- Trial name
- NCT02420262
- Testing
- insulin degludec/liraglutide, insulin glargine, insulin aspart
- Where
- 117 sites in United States, Argentina and 10 more
- Volunteers
- 506 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00039013
- Testing
- AC2993
- Where
- 129 sites in United States
- Volunteers
- 336 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
The hypothesis of this Phase 2, 12-week study, is that DS-8500a will improve glycemic control relative to placebo, based on changes in HbA1c, with acceptable safety and tolerability, in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT02647320
- Testing
- Sitagliptin 100 mg, DS-8500a 25mg
- Where
- 58 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Daiichi Sankyo
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes
This study is conducted in Europe and Asia. The aim of this observational study is to evaluate the effectiveness and the incidence of serious adverse reactions while using Levemir®, NovoMix® and/or NovoRapid® in subjects with…
- Trial name
- NCT00771680
- Testing
- insulin detemir, biphasic insulin aspart 30, insulin aspart
- Where
- 2 sites in Russia, Ukraine
- Volunteers
- 10,408 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise
- Trial name
- NCT00121641
- Testing
- Saxagliptin, Metformin
- Where
- 134 sites in United States, Australia and 4 more
- Volunteers
- 1,035 people
- Sponsor
- AstraZeneca
Type 1 Diabetes, Type 2 Diabetes
A 2-Month Safety Follow-Up Trial
The main purpose of the trial is to evaluate pulmonary function in subjects who had completed any one of the 4 MKC parent trials (MKC-TI-009, MKC-TI-102, MKC-TI-103, or MKC-TI-030) for an additional 2-month safety follow-up.
- Trial name
- NCT00741429
- Testing
- Technosphere Insulin Inhalation Powder, Comparator
- Where
- 150 sites in United States, Brazil and 2 more
- Volunteers
- 649 people
- Sponsor
- Mannkind Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.